

Synergism between Antiplasmid Promethazine and Antibiotics *In Vitro* and *In Vivo*

Joseph Molnár^{1*}, Yvette Mándi¹, Gabriella Spengler¹, Leonard Amaral^{1,2}, Ibolya Haszon³, Sándor Turi³ and Miklós Kásler⁴

¹Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary

²Travel Medicine of the CMDT [Centro de Malaria e Doencas Tropicais], Instituto de Medicina Tropical and Higiene, New University of Lisbon, Lisbon, Portugal

³Department of Pediatrics, University of Szeged, Szeged Hungary

⁴National Institute of Oncology, Budapest, Hungary

*Corresponding author: Joseph Molnár, MD, Ph.D, D.Sc. Institute of Medical Microbiology and Immunobiology, University of Szeged; H-6720 Szeged, Hungary. Tel: +36 62545115; Fax: +36 62545113; E-mail: molnar.jozsef@med.u-szeged.hu

Rec date: May 30, 2014; Acc date: August 21, 2014; Pub date: August 25, 2014

Copyright: © 2014 Joseph Molnár et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Four large groups of antibiotics were developed for different targets of bacterial cells which differ from those of human cells. Uncontrolled use of antibiotics, resistance soon followed. Today, the majorities of bacterial infections are caused by multidrug resistant bacterial isolates and result in serious treatment difficulties. The main cause for antibiotic resistance is the acquisition of plasmids which carry antibiotic resistant genes. These extra-chromosomal genetic elements can be eliminated by phenothiazines from antibiotic resistant bacteria by the selective inhibition of plasmid replication over that of the plasmid carrying bacterium at three different levels or steps as follows: 1. replication of plasmid DNA is destabilized due to the drug induced relaxation of super-helical structure of replicative form of plasmid DNA; 2. inhibition of partition of plasmid DNA during the cell division blocks the rolling circle type of distribution of plasmid into the two daughter cells; 3. inhibition of re-infection of plasmid less bacteria by blocking conjugation. The medical importance of *in vivo* anti-plasmid effects of promethazine was shown, and resulted in synergism between promethazine and gentamycin treatment. The frequently recurring pyelonephritis was cured in children. All the *in vivo* studies employing promethazine described in this review have been approved by Ethics Committee of Clinic and Hospital where therapy took place.

The significance of plasmid elimination *in vitro* provides a method to isolate plasmid-free bacteria for biotechnology without any risks of mutation and opens a new perspective in rational drug design against multidrug resistant bacterial infections.

Keywords: *In vitro* elimination of plasmids; Antibiotic resistance; Metabolic; Virulence plasmids; Promethazine; Plasmid elimination *in vivo*

Introduction

Elimination of plasmids that carry antibiotic resistant genes renders the once infected bacterium susceptible to antibiotics to which the plasmid containing bacterium expressed resistance. Once the plasmid is eliminated, the infection can be treated with commonly available antibiotics which are inexpensive and safe. This new perspective makes “old” antibiotics useful for treatment of antibiotic resistant infections currently resistant due to the presence of plasmids that carry antibiotic resistant genes.

Although the phenothiazine promethazine was initially selected and much studied for its *in vitro* anti-plasmid effects because this compound is widely used in clinical practice and there are no contraindications when used in combination with other therapeutic compounds, other phenothiazines have been studied for potential anti-plasmid properties and some have been shown to express these properties *in vivo*. This review will discuss the development of phenothiazines for plasmid elimination for clinical use. During the last four decades the frequency of antibiotic resistant infections has continued to escalate. Due to this, many antibacterial

chemotherapeutics are deemed to be ineffective globally and this, according to the recent WHO report [1] and presents a serious health problem that affects all countries of the world regardless of economic status. There is thus a recognised urgent need for effective treatment alternatives for antibiotic resistant and multidrug resistant bacterial pathogens. In the herein review, the focus is on one of the mechanisms involved in multi-drug resistance of bacteria, namely, the presence of plasmids within the bacterial pathogen which carry antibiotic resistant genes that result in the resistance phenotype of bacteria. The mechanisms involved in plasmid replication and opportunity to block the plasmid replication *in vitro* and *in vivo* are mainstays of this review. Discussion of different resistance mechanism resulting from antibiotic resistance genes carried by the plasmids, e.g., antibiotic inactivating enzymes, membrane permeability or drug efflux, etc., are excluded from this short review.

Plasmids are extra-chromosomal self-transmissible DNA elements in prokaryotes and some eukaryotic cells. The most important functions of plasmids are related to antibiotic resistance, virulence, metabolic functions of pathogenic and commensal bacteria. The intracellular replication of bacterial chromosome and plasmids are basically different as it was first shown by Jacob et al. [2].

Plasmids are responsible for the self-transmissible antibiotic resistance of bacteria in nature and some of the bacterial plasmids are

responsible for encoding virulence factors [from *Bacillus anthracis* to *Mycobacteria*] including tumorigenesis mediated by IV secretion systems, TGF etc in humans e.g *Bartonella henselae*, *B. quintana*, *Helicobacter pylori* and plants e.g. *Agrobacterium tumefaciens* [3]. A minireview was published by Nóra Gyémánt et al. [3].

Gene mediated metabolic effects of plasmids such as fermentation of sugars, nitrogen fixation in plants, haemolytic effects, etc., are also known for particular plasmids. Other important functions of specific plasmids are the coding for virulence factors [bacteriocins, haemolysins, toxins, etc.] that are responsible for the pathogenicity of Gram negative and Gram positive bacterial species. Tumor induction in man by *Helicobacter pylori* carrying genes that promote damage and inflammatory processes are well known and analogous to tumor induction in plants by plasmid carrying *Agrobacterium* or nitrogen fixation *Rhizobium*. Due to the spreading of antibiotic resistance, new compounds with antibiotic effects are urgently needed against common bacterial infections and tuberculosis as well. As an alternative solution to combat plasmid mediated multidrug resistance of bacteria that cause serious infections and are therapeutically problematic and often untreatable –we must find drugs that target plasmids. These we term anti-plasmid compounds. The process by which anti-plasmid compounds may effectively work is termed plasmid elimination.

At first, plasmids carrying antibiotic resistant genes were eliminated by acridines and ethidium bromide and phenothiazines *in vitro*. However, because these compounds are well known mutagens, they are excluded from *in vivo* use. In this review, the anti-plasmid activity of phenothiazine drugs that are used in clinical practice every day –because of their known property to intercalate to DNA much in the same manner as ethidium bromide and acridines– we have studied these compounds for potential anti-plasmid effects [4-6]. During these studies, it was interesting to note that the growth of various Gram positive and Gram negative bacteria were also inhibited by several phenothiazines e.g chlorpromazine, levo-mepromazine, diethazine and promethazine both *in vitro* and *in vivo* [6]. The bactericidal effect was also shown on *M. tuberculosis* at 50 µg/ml; total destruction of the organism and loss of acid fastness in part of the cells were shown at 300 µg/ml phenothiazines [7]. Preliminary studies in mouse experiments had shown that the phenothiazine derivatives were moderately effective by comparing the mean survival time of *M. tuberculosis* infected mice. Mean survival times of the experimentally infected mice with *M. tuberculosis* No.23296 were found to be between 45 ± 11 and 48 ± 12 days.

The plasmid elimination effect of ethidium bromide, acridine orange and widely used medicines such as the antihistaminic phenothiazine promethazine Pipolphen were compared [4-6]. In those experiments, chlorpromazine was found to be more effective than the acridines. For plasmid elimination we applied tricyclic compounds phenothiazines which were not mutagenic *in vitro* by the direct Ames test [8] and hence if effective, could be considered for *in vivo* human use. Of major importance is that these phenothiazine compounds were subsequently shown to possess anti-mutagenic properties. This was the beginning of a series of experiments in the direction of rational drug design applicable for elimination of antibiotic resistance- and other plasmids for possible use in the medical practice to treat antibiotic resistant infections or to produce plasmid free bacteria for basic biotechnology free of any mutagenic effects. Theoretically, anti-plasmid compounds and antibiotics could have synergistic effects and could be recommended for the treatment of polyresistant infections without the risk of mutagenic effects.

Plasmid curing experiments *in vitro*

Three phenothiazines such as promethazine, chlorpromazine, levopromazine exerted a bacteriostatic, antiproliferative effect on Gram positive, *Mycobacterium tuberculosis* HRV37 bacteria at 10-60 µg/ml, and on Gram negative bacteria at 130-180 µg/ml concentration. Of the three compounds, chlorpromazine had a marked bactericidal effect on cultures of *Bacillus anthracis* growing in minimal medium. In addition, chlorpromazine had a significant bactericidal effect on resting cells of *Escherichia coli* suspended in saline. *Pseudomonas aeruginosa* however, was found to be resistant to phenothiazines. Experiments failed to derive phenothiazine resistant mutants from the highly sensitive *B. anthracis*. An effective plasmid carrying R-factor elimination was observed at a chlorpromazine concentration of 50 µg/ml; the dose somewhat reduced the growth rate of multiple resistant *E. coli* in broth culture [5].

Bacterial species	elimination of
<i>Acinetobacter anitratus</i>	antibiotic resistance
<i>Agrobacterium tumefaciens</i>	tumor inducing ability in plants
<i>Escherichia coli</i>	antibiotic resistance and haemolysin B
<i>Escherichia coli</i>	lactose fermentation
<i>Staphylococcus aureus</i>	antibiotic resistance
<i>Yersinia pseudotuberculosis</i>	antibiotic resistance
<i>Yersinia enterocolitica</i>	virulence
<i>Rhizobium meliloti</i>	nodule formation, N-fixation in plants

Table1: The result plasmids are responsible for various properties of different bacterial species

In the experiments were done to determine the effective phenothiazine structures responsible for F⁺lac plasmid elimination [9]. In another experiment, the inhibition of conjugation, the horizontal R-plasmid transfer from one cell to another was investigated in the presence of chlorpromazine derivatives. Plasmid-curing effect on different compatibility groups of the R-plasmids of *E. coli* was different [10-14].

Two metabolic derivatives of chlorpromazine, the chlorpromazine sulphoxide and 7,8-dioxochlorpromazine had no plasmid curing effect nor did methylene blue. However amitriptyline, 7,8-dioxochlorpromazine and acridine orange were inhibitors of the conjugal transfer of the resistance plasmid, R-144, whilst methylene blue, chlorpromazine sulphoxide, and imipramine had only slight effects on the horizontal plasmid transfer *in vitro*. We were therefore unable to demonstrate a simple correlation between curing ability and inhibition of plasmid transfer amongst the psychoactive drugs tested. A mechanism of plasmid curing by surface action of the drugs was suggested as an alternative to the direct intercalation of the drugs into plasmid DNA. Furthermore it is known that acridines and chlorpromazine are able to intercalate into DNA *in vitro*. Consequently, as previously suggested [11-13], the mechanism of plasmid curing by phenothiazines might be based on an acridine-like intercalation into DNA and retransfer of the eliminated plasmids into the plasmid less daughter cells both *in vitro* and *in vivo*. The partitioning of plasmid into daughter cells was simultaneously blocked by inhibiting the septum formation in the dividing bacteria forming

filaments in the culture and the intercalation were essential for the effective plasmid elimination at “sub growth inhibitory” doses. The inhibition of plasmid replication, partitioning and conjugal transfer of plasmid replication are essential requirements for *in vitro* and *in vivo* plasmid elimination. The procedure did not affect chromosomal replication; however, inhibition of DNA-gyrase was shown. The curing effect was correlation of to the super-delocalizational ability of pi-electrons on the C-8, C-9b and N-atoms of phenothiazines [14,17,18]. Different kinds of plasmids were eliminated from different bacteria with phenothiazines and coordination complexes e.g., multiple antibiotic resistance, haemolysin B, colicine, and F⁺lac plasmid [Table 1] of *E. coli*, calcium-binding protein of *Y. enterocolitica*, tumor inducing plasmid of *A. tumefaciens*, and nitrogen fixation encoding plasmid from *Rhizobium* [6]. An example of the plasmid curing effect by a phenothiazine is presented by Figure 1. Bacterial cells that produce dark blue colonies on EMB agar are cells that contain the F⁺lac plasmid. However when the F⁺lac plasmid carrying bacterial cells were cultured in the presence of a promethazine at sub- inhibitory concentrations for 20-24 hrs, the F⁺lac plasmid was eliminated from the fraction of the initial cell population and these formed pink colonies on the EMB agar plate [9]. The plasmid curing effect of various compounds was dependent on the applied concentrations of curing compounds; pH and the incubation times.



Figure 1: Elimination of F⁺lac plasmid from lactose negative *E. coli*. The F⁺lac operon was deleted by mutation and the F⁺lac plasmid was introduced into cells that were responsible for lactose fermentation by these cells. These cells F⁺lac cells produce dark blue colonies on EMB agar. However when the cells were cultured in the presence of promethazine at sub- inhibitory concentrations for 20-24 hrs, the plasmid was eliminated from the fraction of the cell population and these cells formed pink colonies on the EMB agar plate [9]

It was interesting for us to note that different psychopharmacoons with tricyclic structures had similar antibacterial effects on bacteria and plasmid replication. Some modification in chemical structures of phenothiazines [e.g.sulphoxide] resulted in the loss of plasmid curing effects. However when some naturally occurring “psychopharmacoons or pain killers” e.g cannabis derivatives were studied, the hallucinogenic cannabinoids did not affect plasmid replication and bacterial growth. Only the non-hallucinogenic tetrahydrocannabinolic acid was able to eliminate the bacterial plasmids. This compound had

no effect on the CNS, and had very slight antibacterial effects. Tetrahydrocannabinolic acid was the only agent that expressed plasmid curing effects [15]. Some charge transfer complex formation with the sub-molecular interactions were shown to be responsible for inhibition of plasmid replication [16-18]. As a result of our *in vitro* studies, acridines, ethidium, phenothiazines compounds, proton pump inhibitor trifluoromethyl-ketones were shown to be effective in plasmid elimination of bacteria *in vitro*. But because acridines and ethidium are well known mutagens, these compounds would exert harmful side-effects on the host, and therefore these are excluded for their application *in vivo*. Conversely, certain medicines, e.g., tranquilisers and antidepressants used in everyday medical practice exert a similar antiplasmid effect similar to that of acridine *in vitro*. However the phenothiazines studied were not mutagenic and their copper, palladium and gold coordination complexes had a remarkable anti-mutagenic effectiveness [8] and anti-plasmid effects [13] by shielding DNA base pairs.

The structure activity correlation was evaluated in a series of *in vitro* experiments. The pi-electron structure of each compound was determined by the Hückel method, and its correlation with the anti-plasmid effect was studied by quantitative structure activity relationship [QSAR] multiregression analysis [11,13,17]. We found that the anti-plasmid effect of different ring substituted phenothiazines correlates with the super-delocalization of the pi-electrons on atoms C-8, C-9b and N-10 of the phenothiazines [18,19].

On the basis of the found correlations, some phenothiazine and new anthryl- and phenanthril- compounds were synthesised with anti-plasmid activity [19,20]. Phenothiazines and structurally related drugs were found effective in eliminating various bacterial plasmids [9,21]. Charge transfer complex formation between chlorpromazine and xanthine dyes with different electron acceptor activities [e.g. fluorescein, eosin, erythrosine and rose-bengal] was detected by differential spectrophotometry. Charge transfer complexes were formed between the strong electron acceptor rose-bengal and various tricyclic drugs as well. On the basis of the wavelength shift, the binding energies of drugs and dyes were estimated. Drugs with binding energies in the range of 0.23-2.31 kcal/mol can inactivate plasmid replication systems [15]. A serendipitous discovery led to studies on drugs affecting the central nervous system which also affect the expression of extra-chromosomal plasmids in bacteria. The drugs have a well-defined chemical structure, related electrochemical structures and tranquillizing effect in humans. Although most of the tricyclic drugs were unable to bind covalently to target cells in living systems, promazine was found to form complexes with various compounds, e.g., membranes and nucleic acids [2,3,11]. Tricyclic drugs interfere with energy dependent gyrase activity and promote the relaxation of plasmid DNA, resulting in a cessation in the R plasmid-gene expression and block plasmid replication. These results provide insight into the chemical structures connected with significant specific antimicrobial, so called anti-plasmid effects [8,14]

A special complex formation was found with the covalently closed circular form of plasmid DNA, where GC rich regions of plasmid DNA have higher affinity for anti-plasmid phenothiazines than adenine-thymine rich regions of plasmid DNA. Because the G-C rich regions have a special role in the DNA stability via three hydrogen bonds, it was supposed that these regions could have a key role in the plasmid stability and replication [17,18].

Plasmid DNA becomes more rigid due to the intercalated phenothiazine molecules and strand breaks occur that lead to the

formation of non-replicative forms open, circular or linear derivatives of CCC form [called covalently closed circular DNA]. It is known that open circular forms or linear forms of CCC form of plasmid DNA cannot start to replicate from the origin of the promoter region due to the relaxed form of plasmid DNA [8,16]. Based on these observations new anthril- compounds were synthesized [19,30]. It was surprising that some natural compounds isolated from essential oils of the peppermint oil exhibited antimicrobial and anti-plasmid activities. The anti-plasmid compounds were isolated and identified as menthol [22]. Their effect was comparable to the promethazine *in vitro*. There are a number of pharmacologically active tricyclic compounds, many of which are in regular clinical use. Some of them have been demonstrated to exhibit various antimicrobial activities. They inhibit the growth of pathogenic bacteria, causing a general increase in membrane permeability, have antibacterial effects on *Salmonella*, *Staphylococcus*, *Escherichia coli* and *Yersinia enterocolitica* cells [6,18,23,24]. It was shown that phenothiazines exhibited antibacterial affect *in vitro* and *in vivo* as well [5, 6].




Figure 2: Results of antibiotic resistance plasmid elimination *in vitro* by promethazine. The figure shows two plates as a model of the elimination of R antibiotic resistance plasmid from *E.coli*. The kanamycin resistant *E. coli* cells were cultured in the presence of sub-inhibitory doses of phenothiazines [e.g. promethazine] or other tricyclic compounds and the cultures were incubated at 37°C for 20-24 hrs. Then dilutions were made from the cultures and 0.1ml was plated to nutrient agar plates from each dilutions. The plates were incubated for 24 hours at 37°C were considered as master plates. The countable developed colonies were transferred by Lederberg methods with velvet replica to Kanamycin containing nutrient agar. This Km- nutrient agar plates were then incubated further for 24 hrs at 37°C and the position and number of developed colonies were compared to the master plate. The missing colonies from antibiotic containing plate, which were not able to grow on the kanamycin, those were the plasmidless colonies, those lost the antibiotic resistance plasmid at 37°C. [3,4,5].

The inhibition of plasmid replication and transfer can be the theoretical basis for decrease of bacterial plasmid replication in nature as well, where the gram negative bacteria can mediate the transmission of various plasmids in the nature. In this aspect there is a certain similarity between plasmids and viruses [18].

The role of charge distribution on the phenothiazines in the anti-plasmid and antiviral effects was compared. The main aim was to design drugs without effects on the central nervous system – and this may open up a new way in the experimental chemotherapy.

***In vivo* experiments for plasmid elimination**

Before the introduction of plasmid curing *in vivo*, the phenothiazine compounds were selected and basic clinical investigations were performed e.g., the antibiotic sensitivity of individual bacteria from the urine of non-treated and treated patients were compared. In these experiments the urine or other biological samples [pus] were serially diluted and 100 µl of each dilution were plated to nutrient agar and the plates were then incubated at 37°C to allow the growth a visible colony from each bacterial cell. The colonies grown on the master plates were transferred to antibiotic containing nutrient agar by using the Lederberg replica plating transfer method [25] and plasmid elimination from specific colonies readily demonstrated with clinical isolates from non-treated patients and patients treated with antibiotics plus phenothiazines [25-27]. These results gave rise to the possibility of a new type of combination therapy for antibiotic resistant bacterial infections mediated by then presence of plasmids carrying antibiotic resistant genes; the combination of traditional antibiotics with anti-plasmid phenothiazines.

The anti-plasmid action of phenothiazine and structurally related compounds was shown by elimination on the model F⁺lac plasmid of *E. coli* in model experiments. The first studies of successful plasmid elimination by promethazine in human patients were described in 1981- 1982 [26-28].

In our former experiments, the conditions for plasmid eliminations were defined. For studies investigating the *in vivo* anti-plasmid effects of a phenothiazine, the phenothiazine promethazine was selected because of its wide and safe use in everyday medical practice. This phenothiazine antihistamine and antiemetic has no remarkable side effects on the central nervous system as a consequence of symmetric pi- electron distribution in the skeleton of the phenothiazine. This phenothiazine was used to potentiate the antimicrobial effects of different antibiotics in various urogenital clinical infections in the Clinic of General Surgery at the Department of Nephrology, at University of Szeged. [28]. Promethazine, - a phenothiazine-derivative – was given to patients presenting with a urogenital infection. This treatment resulted in the pathogenic bacteria in the urine to become sensitive to gentamicin and some other antibiotics to which they had been resistant before the administration of promethazine.

According to the phage-type, the bacteria before and after treatment with Pipolphen belonged to the same strain [26,28]. In addition to the R plasmid elimination, synergism between promethazine and gentamicin was also shown. Due to these results, we supposed that the membrane permeability of gentamicin could be enhanced by the presence of promethazine and Promethazine Pipolphen was successfully applied in the clinical practice with 22 patients presenting with urogenital bacterial infections.

The pathogen was isolated from the first urine sample of the patients and the antibiotic sensitivity was determined. From the patients, 22 samples yielded resistant pathogens to 7 different antibiotics.

Of the 22 patients, 14 stayed in the clinic for 17 days and the patient's urines were checked continuously every day for bacteria and

the bacteria isolated were studies resistance to gentamycin resistance. After 7 days of treatment all the patients were cured from the infection and recurrent infections were not observed. The mechanism of synergistic action of the drug interaction on cell membrane permeability was not studied in detail, but the disappearance of clinical symptoms and bacteriuria caused by gentamycin resistant Gram negative pathogens [*E. coli*, *Klebsiella*, *Acinetobacter*] was established [26-28].

***In Vivo* Studies in pediatric and adult patients**

Indeed tricyclic psychopharmacons contain not only a wide spectrum of agents that differ chemically and pharmacologically, but also in terms of interaction with various macromolecules of different cells. Among the well-known phenothiazines, promethazine has been the most extensively studied. In a series of investigations promethazine has been administered to pregnant women for its antiemetic effect.

Finally, the effects of promethazine were studied in forty children with frequently recurring pyelonephritis aged 9.9 ± 4.2 years in the Pediatric Clinic at the Department of Nephrology at University of Szeged [29]. No significant difference in age and sex was between the 3 groups. None of the cases involved urological abnormalities. The patients were divided in three groups for the treatments. The results of three methods of treatment were compared:

The medical importance of *in vivo* antiplasmid effects of promethazine was shown, and resulted in synergism between promethazine and gentamycin treatment. The frequently recurring pyelonephritis was cured in children. All the *in vivo* studies employing promethazine described in this review have been approved by Ethics Committee of Clinic and Hospital where therapy took place. For the *in vivo* studies we had 3 groups of patients.

In group 1 for combination therapy 10 children were given a combination of gentamycin and promethazine for 7 or 10 days. The daily dose of promethazine was 2 mg/kg orally, divided into two doses on days 1 and 2, and 1 mg/kg in one dose for the following 5 days. Gentamycin was administered i.m. in a daily dose of 4 mg/kg in two divided doses for the following [Group 1]. The bacterial infections were successfully cured.

In the Gentamycin control group 11 patients received gentamycin treatment alone [i.m.], alone in the same dosage as in Group 1 for 10 days [Group 2].

In Group 3, 19 children received long term antibiotic prophylaxis with episodes of intensive treatments for recurrence for two weeks in a full dose of antibiotics according to the antibiotic susceptibility test [Group 3] were on long-term traditional oral antibiotic prophylaxis [5.6 ± 2.1 years] with episodes of intensive treatment of recurrences. The number of recurrences in Group 1 was 3.

The number of recurrences in Group 2 was 27 during the 3 years; new scars were not observed in any of the patients from this group.

In a 3-year follow-up period, the number of pyelonephritis recurrences was significantly lower in Group 1 than in Groups 2 and 3. In the 3rd group, six out of 19 children had renal scarring. The authors suggest a synergistic effect between gentamycin and promethazine therapy. Promethazine increases antibiotic sensitivity, which could contribute to the elimination of antibiotic resistant pathogens.

In previous studies we reported that promethazine and other phenothiazines are able to eliminate the antibiotic resistance plasmid

of *E. coli in vitro* and *in vivo* [23-26]. The antibiotic resistance plasmids allow the multiplication of bacteria in the presence of antibiotics which makes the antibiotic treatment insufficient. Plasmid curing was supposed to improve the opportunities of chemotherapy.

The practical importance of plasmid elimination in antimicrobial chemotherapy was supported by the studies where the plasmid curing effects of promethazine was induced in mixed bacterial cultures e.g. in the presence of *S. epidermidis* and *B. cereus*. The interactions between coexisting bacterial species did not reduce the frequency of plasmid curing by promethazine in mixed cultures with *S. epidermidis* or *B. cereus in vitro* [30].

In conclusion, we have demonstrated the role of plasmid elimination with combination chemotherapy by sensitizing the bacterial cells to antibiotics. Elevating the penetration of some antibiotics into bacterial cells also can be a component to be considered in the rational drug design against multidrug resistant bacterial infections by the simultaneous application of anti-plasmid compounds and antibiotics.

Anti-plasmid effect of structurally similar maproptiline, amitriptyline to phenothiazines has also been shown in the patients. Based on on-going research *in vivo* studies, some new results will be reported in a forthcoming publication together with implication of combinations of anti-plasmid compounds with antibiotics to improve the therapy of various acute and chronic bacterial infections.

References

1. World Health Organization [WHO] (2014) Antimicrobial resistance: global report on surveillance. [ISBN 978 92 4 156474 8] Geneva, Switzerland.
2. Jacob F, Brenner S, Cuzin F (1963) on the regulation of DNA replication. *Cold Spring Harbour Symp Quant Biol* 28: 329-348.
3. Gyémánt N, Molnár A, Spengler G, Mándi Y, Szabó M, et al. (2004) Bacterial models for tumor development. Mini-review. *Acta Microbiol Immunol Hung* 51: 321-332.
4. Molnár J, Király J, Mándi Y (1975) The antibacterial action and R-factor-inhibiting activity by chlorpromazine. *Experientia* 31: 444-445.
5. Molnár J, Mándi Y, Király J (1976) Antibacterial effect of some phenothiazine compounds and R-factor elimination by chlorpromazine. *Acta Microbiol Acad Sci Hung* 23: 45-54.
6. Molnár J, Földeák S, Nakamura MJ, Rausch H, Domonkos K, et al. (1992) Antiplasmid activity: loss of bacterial resistance to antibiotics. *APMIS Suppl* 30: 24-31.
7. Molnár J, Földeák S, Nakamura MJ, Rausch H, Domonkos K, et al. (1992) Antiplasmid activity: loss of bacterial resistance to antibiotics. *APMIS Suppl* 30: 24-31.
8. Molnár J, Béládi I, Földes I (1977) Studies on antituberculous action of some phenothiazine derivatives *in vitro*. *Zentralbl Bakteriol Orig A* 239: 521-526.
9. Tanaka M, Molnár J, Kidd S (1997) Antimutagenicity of phenothiazine-metal co-ordination complexes in chemically induced mutagenesis. *Anticancer Res* 17: 381-385.
10. Mándi TY, molnár J, Holland IB, Béládi I (1975) Efficient curing of an *Escherichia coli* F-prime plasmid by phenothiazines. *Genet Res* 26: 109-111.
11. Mándi Y, Molnár J, Holland IB (1980) The effect of chlorpromazine on plasmid replication, plasmid transfer and sex pili of *E. coli*. *Acta Microbiol Acad Sci Hung* 28: 205-210.
12. Molnár J, Domonkos K, Mándi Y, Földeák S, Holland IB (1980) Possible mechanism plasmid elimination by phenothiazines and related drugs in Usdin, Eckert, Forrest, eds. *Phenothiazines and structurally related drugs*:

- Basic and Clinical Studies, Elsevier North Holland, Inc. Amsterdam, pp. 115-118.
13. Molnár J, Schneider B, Mándi Y, Farkas S, Holland IB (1980) New mechanism of plasmid curing by psychotropic drugs. *Acta Microbiol Acad Sci Hung* 27: 309-315.
 14. Molnár J, Földeák S (1989) Antiplasmid action of phenothiazines and related compounds. Extracted the Proceedings of the 16th International Congress of Chemotherapy, Jerusalem, Israel, p. 343.
 15. Kidd S, Humbley TW, Hevér A, Nelson MJ, Molnár J (1996) The antiplasmid action of some palladium [II] complexes of phenothiazine based pharmaceuticals and the crystal structure promoted trichloro [10-[3'-dimethylaminopropyl] phenothiazine-S] palladium [II]. *J Inorg Biochem* 62: 171-181.
 16. Molnár J, Nakamura J (1985) Effect of Cannabis derivatives on plasmid replication in *Escherichia coli*. *Res. Communications in Substances of Abuse*, 6: 23-35.
 17. Molnár J, Földeák S, Nakamura MJ, Gaizer F, Gutmann F (1991) The influence of charge transfer complex formation on the antibacterial activity of some tricyclic drugs. *Xenobiotica* 21: 309-316.
 18. Molnár J (1986) Fenothiazinok és hasonló szerkezetű vegyületek antibakteriális, valamint plasmid replikációt gátló hatásai Hungarian Academy of Sciences, Budapest, p.1-184.
 19. Molnár J (1990) The role of charge distribution of the tricyclic compounds in the antibacterial, antiviral and antiplasmid effects. *Electropharmacology* p. 205-218.
 20. Molnár J, Földeák S, Hegyes P, Schneider B, Holland IB (1979) New plasmid curing compounds. Anthril and phenathril derivatives. *Biochem Pharmacol* 28: 261-265.
 21. Spengler G, Molnár A, Schelz Z, Amaral L, Sharples D, et al. (2006) The mechanism of plasmid curing in bacteria. *Curr Drug Targets* 7: 823-841.
 22. Miskolci C, Labádi I, Kurihara T, Motohashi N, Molnár J (2000) Guanine-cytosine rich regions of plasmid DNA can be the target in anti-plasmid effect of phenothiazines. *Int J Antimicrob Agents* 14: 243-247.
 23. Schelz Z, Molnár J, Hohmann J (2006) Antimicrobial and antiplasmid activities of essential oils. *Fitoterapia* 77: 279-285.
 24. Csiszar K, Molnár J (1992) Mechanism of action of tricyclic drugs on *Escherichia coli* and *Yersinia enterocolitica* plasmid maintenance and replication. *Anticancer Res* 12: 2267-2272.
 25. Molnár J, Nakamura MJ (1988) Virulence associated plasmid and R-plasmid curing in *Yersinia enterocolitica* by some tricyclic compounds. *Acta Microbiol Hung* 35: 307-312.
 26. LEDERBERG J, LEDERBERG EM (1952) Replica plating and indirect selection of bacterial mutants. *J Bacteriol* 63: 399-406.
 27. Kásler M, Molnár J, Poczik M, Romhányi R (1981) On the synergism of Pipolphen with antibiotics possible elimination of an "R" plasmid in vivo. *Sejtosztódás Farmacológiája X/1*, Eds. Hernádi Ferenc és Kovács Péter, In Hungarian with summary in English, Hajduszoboszló, Hungary p. 141-151.
 28. Kásler M, Molnár J, Poczik M (1982) A Pipolphen plasmid törlo hatásának vizsgálata urogenitalis fertozések esetén. *Urol Nephrol. Szle* 9: 130-133.
 29. Kásler M, Molnár J, Ágoston É, Poczik M (1982) A Gentamycin-Pipolphen gyógyszer-kombináció alkalmazásának tapasztalatai polyresistens baktériumtörzsek okozta urogenitális fertozésekben. *Urol Nephrol Szle* 9: 135-138.
 30. Molnár J, Haszon I, Bodrogi T, Martonyi E, Turi S (1990) Synergistic effect of promethazine with gentamycin in frequently recurring pyelonephritis. *Int Urol Nephrol* 22: 405-411.
 31. Molnár A, Amaral L, Molnár J (2003) Antiplasmid effect of promethazine in mixed bacterial cultures. *Int J Antimicrob Agents* 22: 217-222.